Sidney Taurel
Sidney Taurel
Sidney Taurelis a Moroccan-born American businessman. He is the former Chairman and Chief Executive Officer of Eli Lilly and Company. He became chief executive officer in July 1998 and chairman of the board of directors on January 1, 1999. He was succeeded as chief executive officer by John C. Lechleiter on April 1, 2008. He now serves as an advisor at Moelis & Company...
data erosion months nearly product prozac sales severe
With nearly two months of Prozac sales data available, the erosion in prescriptions is the most severe ever for a blockbuster product in our industry,
lives saving thousands
We're going to be saving hundreds of thousands of lives with this product,
completion confidence continued future high initiation level rapid reflect share
The rapid completion of the share repurchase program, coupled with the initiation of a new program, reflect the board's continued high level of confidence in the future of the company.
best company customer deliver help leadership people position role step sure team throughout
We want to be sure that our leadership team is in the best position to help people throughout the company deliver for the customer now and in the future. John's new role is an important step in making that happen.
ability add area bar behind bench dedication drive increase leadership leaves performance pivotal raise strong throughout transform valued
Charlie's leadership was pivotal in our drive to increase productivity in every part of Lilly. His ability to transform our organization and raise the bar in every area of performance has been invaluable. His dedication to leadership development is also evident. He leaves behind a strong bench of valued leaders who add value throughout the company.
advantage attractive combined enhance focus found offer pcs rite taking value
By taking advantage of this opportunity, Lilly will be able to enhance its focus on pharmaceutical innovation, ... We found Rite Aid's offer attractive because of its value to Lilly and the many synergistic opportunities PCS will have when combined with Rite Aid.
access increase people poor short
In the short term, I think this will increase access to some people who are not poor enough to be on Medicaid,
fine hope push stopped
I hope they won't push too much farther. If they stopped right now, it'd be fine with me.
access affordable assistance earthquake ease employees ensure essential forward gave groups halt health hurricane improve offered patients save seniors share six spread stepped suffering urgent year
In a year of urgent needs, Lilly and its employees stepped forward with extraordinary efforts. To ease the suffering of hurricane and earthquake victims, we gave essential medicines, cash, and supplies. To ensure that seniors and low-income patients had affordable access to drugs, we offered six patient assistance programs. And to halt the spread of multi-drug-resistant tuberculosis, we partnered with the World Health Organizations and other groups to share expertise, improve treatment, and save lives.
help means products weather
That means up to 10 products that will be launched between 2001 and 2004, which will help us weather the storm,
combined continues dependent five fully growth introduced last less line major percent performance product products prozac rate sales
As our product line continues to become more diversified, we have become less dependent on Prozac performance. Major products introduced in the last five years accounted for fully one-third of our sales in 1999 and had a combined growth rate of 41 percent during the year.
broad built business challenges charlie company financial help internal judgment past reputation sound steer strong
During his tenure, Charlie used his broad business experiences and sound judgment to help steer the company through many challenges over the past decade. Through Charlie's leadership, we have built a world-class financial organization and strengthened Lilly's reputation for sound financial operations, transparency in our financial reporting, and strong internal controls.
believe confirm iii looks phase seen successful trials
It looks very, very promising, ... We believe that if the Phase III trials confirm what we have seen so far, this would be a very successful product.
dose patient
the right dose of the right drug to the right patient at the right time.